Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2024 financial results on Thursday, August 1, 2024, at 8:30 a.m. ET.
2024年7月18日，馬薩諸塞州沃爾瑟姆（WALTHAm）（全球新聞通訊社）-- apellis pharmaceuticals今日，APLS公司（納斯達克：APLS）宣佈將於2024年8月1日星期四上午8:30（美國東部時間）舉行電話會議和網絡直播，討論該公司2024年第二季度的財務業績。
To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event.
如欲通過電話收聽實況，請預先註冊。這裏參與者還可以通過該公司網站“投資者與媒體”欄目下的“活動和展示文稿”頁面獲得活動的現場音頻網絡直播及幻燈片。網絡直播重播將在活動結束後的90天內提供。
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit or follow us on Twitter and LinkedIn.
關於Apellis
Apellis Pharmaceuticals是一家全球生物製藥公司，結合勇敢的科學和同情心，爲一些最具挑戰性的疾病患者開發改變生命的治療方案。我們推出了15年來第一個新的補體藥物系，現有兩種針對C3的批准藥物，其中包括全球首款用於地理萎縮症的治療。我們相信，我們才剛剛開始釋放針對C3治療嚴重眼部、罕見和神經系統疾病的潛力。欲了解更多信息，請訪問或關注我們的Twitter和LinkedIn。
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
投資者聯繫人：
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
譯文內容由第三人軟體翻譯。